Driving research of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS),
Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia and Long Covid

Open Medicine Foundation Australia Ltd  (OMFAU) is a regional branch entity of Open Medicine Foundation, and is part of the largest, concerted worldwide nonprofit effort to diagnose, treat and find a cure for ME/CFS.

OMF Australia is a Public Ancillary Fund, established for the purpose of promoting and funding research into chronic complex diseases, and supports the Melbourne ME/CFS Collaboration.

About the research center

Established in 2020, the Melbourne ME/CFS Collaboration is directed by Christopher W. Armstrong, PhD.

“We are tremendously grateful for the generous support from Emerge Australia, our Australian partner. Emerge Australia is a national organization providing information, support, and advocacy for people with ME/CFS — giving hope and help to more than 250,000 Australians living with the disease,”

Linda Tannenbaum, OMF Founder & CEO/President

The Melbourne ME/CFS Collaboration  seeks to characterize the unifying biological pathways of ME/CFS that relate to the shared disease experience between patients while also understanding each patient’s unique biology that creates variation in disease experience and severity.

Chris Armstrong, PhD, was OMF’s Science Liaison and a Visiting Scholar at Stanford. He completed his PhD in Biochemistry at the University of Melbourne, and has been involved with researching ME/CFS for over a decade. 

Dr. Armstrong is most well known for his research using metabolomics to observe biochemical alterations in ME/CFS patients. He began his work in this field at the University of Melbourne, beginning a PhD project to apply metabolomics to study  (ME/CFS) and published his first metabolomics study on blood and urine in 2015.

Since then Chris has set up collaborative efforts to apply metabolomics to immunological experiments on ME/CFS, observing how metabolism may relate to immune cell function. He has also focused on longitudinal research in ME/CFS while looking to extend metabolic capabilities across the field of ME/CFS to help collate different patient group

Core Aims

Develop

methods to understand the biology of the individual with ME/CFS.

Translate

understanding of the disease into practical treatment approaches.
 

Determine

the unifying biology between ME/CFS patients.

Understand

the development of ME/CFS in children and teenagers.

Reveal

the biology underlying ME/CFS symptoms.

Build

tools for research and treating ME/CFS.

Fundamental Philosophy

  • Every individual is biologically unique.
  • Disease biology is dynamic, not static.
  • Metabolism is strongly associated with symptom expression.
  • Define research questions and develop a research plan to answer them.
  • Measure the biology as it occurred in the body where possible.
  • Use extensive observations and data to generate hypotheses.
  • Translate research to tools that can be accessible to other researchers and clinicians.
  • Bring young scientists and clinicians into the research field.
  • Collaborate with experts out of our field and use their expertise.
  • Research biology at many layers, from biochemistry to cells to tissues

View our latest news

Newsletter February 2021

An Update from Chris Armstrong, Director, Melbourne ME/CFS Collaboration The Melbourne ME/CFS Collaboration is the fifth and newest OMF funded collaborative research center. After making

studies

Nitrogen Hypothesis

This project aims to test the nitrogen hypothesis, which is that damaging, nitrogen-containing by-products of energy metabolism accumulate more readily in the cells of ME/CFS patients.

Read More

Scientific Team

To carry out these ambitious projects, Dr. Armstrong is establishing networks and collaborations extending to USA, UK, Sweden, and other Australian institutions. 

University of Melbourne, Australia

Christopher Armstrong, PhD

Paul Gooley, PhD

Neil McGregor, PhD

Natalie Thomas, PhD

Kathy Huang

David Ascher, PhD

Elisha Josev, PhD

Sarah Knight, PhD

Adam Scheinberg, MD

David Stroud, PhD

 

Stanford University, USA

Ronald Davis, PhD

Robert Phair, PhD

Laurel Crosby, PhD

Julie Wilhelmy

Amit Saha, PhD

Layla Cervantes

Anna Okumu

Mike Snyder, PhD

Ryan Kellogg, PhD

Jaime Seltzer

 

Uppsala University, Sweden

Jonas Bergquist, MD, PhD

 

Massachusetts General Hospital, USA

Ronald Tompkins, MD, ScD

Wenzhong Xiao, PhD

 

University of Montreal, Canada

Alain Moreau, PhD

 

Open Medicine Foundation

Linda Tannenbaum

 

UC San Diego, USA

Robert Naviaux, MD, PhD

 

University of Alabama Birmingham, USA

Jarred Younger, PhD

 

University College London, UK

Jo Cambridge, PhD

 

La Trobe University, Australia

Sarah Annesley, PhD

Paul Fisher, PhD

Daniel Missailidis

 

Australian National University, Australia

Brett Lidbury, PhD

Alice Richardson, PhD

 

Monash University, Australia

Joanne Fielding, PhD

Meaghan Clough, PhD

 

Macquarie University, Australia

Gilles Guillemin, PhD

SUPPORT OMF Funded Critical Research

Please help us expand our research efforts across the globe. Every donation brings us closer to a fully-funded research effort and the answers we all seek.

Learn about Our Other OMF Funded Collaborative Research Centers

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

 

Averting a second pandemic:

Open Medicine Foundation leads groundbreaking international study of

Long COVID’s conversion to ME/CFS

AGOURA HILLS, CALIF.  — Open Medicine Foundation (OMF) is leading a large-scale international collaborative study investigating the potential conversion of Post-Acute Sequelae SARS-CoV-2 infection — more commonly known as Long COVID or Post-COVID Syndrome —  to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a chronic, life-altering disease with no known cause, diagnostic test or FDA approved treatments available.

Up to 2.5 million people in the U.S. alone suffer from ME/CFS; the COVID-19 pandemic could at least double that number. An estimated 35 percent of Americans who had COVID-19 have failed to fully recover several months after infection, prompting many to call it “a potential second pandemic.”

OMF recognized a familiar health crisis emerging, one with eerie similarities to ME/CFS. This crisis presented a unique opportunity to understand how a viral infection — in this case COVID-19 — may develop into ME/CFS in some patients. The goal is to find targeted treatments for ME/CFS patients and ultimately prevent its onset in people infected with SARS-CoV-2 or other infections.

The federal government is only now investing in Post-COVID research, with no focus on its connection to ME/CFS. OMF has already engaged researchers for the largest-scale study of its kind, solely supported by private donors who have contributed over one million dollars to date. When fully funded, the five million dollar, three-year study will be conducted across the globe at OMF funded Collaborative Research Centers, led by some of the world’s top researchers and ME/CFS experts.

BACKGROUND

In a significant percentage of patients, infections preceded their development of ME/CFS.  For example, according to the CDC about one in ten infected with Epstein-Barr virus, Ross River virus, or Coxiella burnetti develop symptoms that meet the criteria for ME/CFS.

THE STUDY

The ability to follow the development of ME/CFS from a known viral infection is unprecedented to date and crucial to researchers’ understanding of the disease. The focus of this study is to find the biological differences between persons returning to good health after COVID-19 and persons who remained ill more than six months after infection and developed ME/CFS.  Understanding these alterations in key pathways can lead to groundbreaking discoveries including new biomarkers, drug targets, and prevention and treatment strategies.

###

About Open Medicine Foundation

Established in 2012, Open Medicine Foundation leads the largest, concerted worldwide nonprofit effort to diagnose, treat, and prevent ME/CFS and related chronic, complex diseases such as Post Treatment Lyme Disease Syndrome, Fibromyalgia, and Post COVID. OMF adds urgency to the search for answers by driving transformational philanthropy into global research. We have raised over $28 Million from private donors and facilitated and funded the establishment of five prestigious ME/CFS Collaborative Research Centers around the world. To learn more, visit www.omf.ngo.

CONTACT:

Heather Ah San

Development and Communications Manager

1-650-242-8669

heather@omf.ngo